查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541461

2024-2032 年医院感染治疗市场报告（按药物类型、适应症和地区）

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年，全球医院感染治疗市场规模达125亿美元。多重抗药性感染发生率的不断上升、对抗菌药物管理的日益重视、研发 (R&D) 的不断进步以及全球医疗保健支出和基础设施发展的增加是影响市场成长的一些关键因素。

医院感染治疗市场分析：

市场成长与规模：在医院获得性感染发生率不断上升以及对有效治疗解决方案的需求的推动下，全球医院感染治疗市场正在经历强劲增长。在全球医疗支出和基础设施发展不断增长的推动下，市场规模正在稳步扩大。

主要市场驱动因素：主要驱动因素包括多重抗药性感染的流行、抗菌药物管理计划意识的增强、研发的持续进步以及全球医疗保健支出的增加。

技术进步：持续的技术进步，特别是在基因组学、微生物学和免疫学方面，正在有助于发现新的药物标靶和开发先进的医院感染疗法，例如单株抗体和联合疗法。

产业应用：医院感染治疗适用于各种适应症，包括血流感染、泌尿道感染 (UTI)、手术部位感染、肺炎等，解决与每个类别相关的特定挑战。

主要市场趋势：对抗菌药物管理的日益关注、增加研究合作、併购以扩大产品组合，以及开发传统类别之外的替代疗法是加强市场成长的一些新兴趋势。

地理趋势：从地理上看，在强大的医疗基础设施和严格的监管框架的推动下，北美和欧洲的需求处于领先地位。由于医疗保健投资和基础设施发展的增加，亚太地区正在见证显着成长。

竞争格局：医药企业研发、策略合作、併购等竞争格局激烈。强调使产品符合抗菌管理原则，从而塑造产业策略。

挑战与机会：抗药性菌株的出现为市场发展带来了挑战，而机会则在于解决医院感染范围内的特定适应症并利用技术创新进行治疗开发。

医院感染治疗市场趋势：

院内感染 (HAI) 的发生率不断增加：

医院感染治疗市场的主要驱动力之一是医院感染发生率的上升。这些感染本质上可以是细菌、病毒或真菌，通常与侵入性医疗程序、手术或医疗设备的使用有关。 HAI 的流行是全球关注的一个主要问题，导致对管理和治疗这些感染的有效疗法的需求增加。除此之外，抗药性病原体在医疗机构内的传播进一步加剧了对先进和有针对性的治疗方案的需求，因此需要开发创新和有效的疗法来有效对抗这些感染。

对抗菌药物管理计划的认识不断增强

抗菌药物管理计画作为对抗抗菌药物抗药性的出现和传播的关键策略而受到重视。这些计划的重点是优化抗菌药物的使用，以改善患者的治疗效果，同时最大限度地减少抗药性的产生。人们对抗菌药物管理的认识不断增强，人们越来越重视新型疗法的开发和采用，这些疗法可以解决抗药性病原体带来的具体挑战，从而为市场扩张创造了积极的前景。此外，全球各医疗保健组织和监管机构正在积极促进抗菌药物管理，以确保明智地使用抗生素和其他抗菌药物，从而推动市场成长。

研发活动取得重大进展

传染病领域持续的研发活动为医院感染治疗市场的扩张做出了重大贡献。与此一致的是，基因组学、微生物学和免疫学的进步为感染机制和新药物标靶的识别提供了宝贵的见解。新抗菌化合物的发现和联合疗法的开发有助于市场扩张。除此之外，製药公司、学术机构和研究组织之间的广泛合作推动了创新治疗方式的发现和开发，包括单株抗体、疫苗和新型抗生素，从而推动了市场成长。

医疗保健支出增加和基础设施发展

全球医疗保健支出的增加和医疗保健领域持续的基础设施发展正在推动医院感染治疗市场的成长。同时，许多政府和私人投资者正在投资扩大和现代化医疗保健设施，包括医院和诊所。这反过来又推动了对感染治疗药物的需求，为医疗保健提供者提供有效的工具来管理和控制 HAI 的发病率，从而促进市场成长。此外，新兴经济体医疗基础设施的扩张为医院感染治疗开闢了新市场。随着医疗保健服务的改善，对先进治疗方案的需求激增，以解决与传染病相关的医疗保健挑战。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球医院感染治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 抗菌药物
    • 市场趋势
    • 市场预测
  • 抗真菌药物
    • 市场趋势
    • 市场预测
  • 抗病毒药物
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依迹象

  • 血流感染
    • 市场趋势
    • 市场预测
  • 泌尿道感染
    • 市场趋势
    • 市场预测
  • 手术部位感染
    • 市场趋势
    • 市场预测
  • 肺炎
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Allergan Plc (AbbVie Inc.)
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A2393

The global hospital infection therapeutics market size reached US$ 12.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.55% during 2024-2032. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Analysis:

Market Growth and Size: The global hospital infection therapeutics market is experiencing robust growth, driven by an increasing incidence of hospital-acquired infections and the demand for effective treatment solutions. The market size is expanding steadily, fueled by rising healthcare expenditure and infrastructure development worldwide.

Major Market Drivers: Key drivers include the prevalence of multidrug-resistant infections, growing awareness of antimicrobial stewardship programs, continuous advancements in R&D, and a rise in healthcare expenditure globally.

Technological Advancements: Ongoing technological advancements, particularly in genomics, microbiology, and immunology, are contributing to the discovery of novel drug targets and the development of advanced hospital infection therapeutics, such as monoclonal antibodies and combination therapies.

Industry Applications: Hospital infection therapeutics are applied across various indications, including bloodstream infections, urinary tract infections (UTI), surgical site infections, pneumonia, and others, addressing specific challenges associated with each category.

Key Market Trends: The rising focus on antimicrobial stewardship, increasing research collaborations, mergers and acquisitions to expand product portfolios, and the development of alternative therapeutics beyond traditional categories are some of the emerging trends strengthening the market growth.

Geographical Trends: Geographically, North America and Europe lead in demand, driven by robust healthcare infrastructures and stringent regulatory frameworks. While Asia Pacific is witnessing significant growth due to increased healthcare investments and infrastructure development.

Competitive Landscape: The competitive landscape is intense, with pharmaceutical companies engaged in R&D, strategic collaborations, and mergers and acquisitions. The emphasis on aligning products with antimicrobial stewardship principles shapes industry strategies.

Challenges and Opportunities: The emergence of drug-resistant strains is creating challenges for market development, while opportunities lie in addressing specific indications within the hospital infection spectrum and leveraging technological innovations for therapeutic development.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on drug type and indication.

Breakup by Drug Type:

Anti-bacterial Drugs

Anti-fungal Drugs

Anti-viral Drugs

Others

Anti-bacterial drugs accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes anti-bacterial, anti-fungal, anti-viral, and other drugs. According to the report, anti-bacterial drugs represented the largest segment.

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

Blood Stream Infections

Urinary Tract Infections

Surgical Site Infections

Pneumonia

Others

Surgical site infections holds the largest share of the industry

A detailed breakup and analysis of the market based on the indication have also been provided in the report. These include blood stream infections, urinary tract infections, surgical site infections, pneumonia, and others. According to the report, surgical site infections accounted for the largest market share.

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Allergan Plc (AbbVie Inc.)

AstraZeneca Plc

Bayer Aktiengesellschaft

Bristol-Myers Squibb Company

F. Hoffmann-La Roche AG (Roche Holding AG)

Gilead Sciences Inc.

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co. Inc

Pfizer Inc.

Sanofi S.A.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

In December 2023, F. Hoffmann-La Roche AG (Roche Holding AG) entered into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California.

In October 2023, Gilead announced its collaboration with Assembly Biosciences to advance the research and development of novel antiviral therapies, with an initial focus on Assembly Bio's established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).

In March 2023, GSK plc and SCYNEXIS, Inc. announced that they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and reduction in the incidence of recurrent VVC (RVVC).

Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive hospital infection therapeutics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the hospital infection therapeutics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the hospital infection therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hospital infection therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players